...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of neurology: the official journal of the European Federation of Neurological Societies >The Parkinson's Disease Composite Scale: results of the first validation study
【24h】

The Parkinson's Disease Composite Scale: results of the first validation study

机译：帕金森病复合标尺：第一次验证研究的结果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and purpose The aim was to validate the Parkinson's Disease Composite Scale ( PDCS ). Methods The study included 194 Parkinson's disease ( PD ) patients in five countries. Investigators completed the following scales: PDCS , the Movement Disorder Society Unified Parkinson's Disease Rating Scale ( MDS ‐ UPDRS ), Parkinson's Disease Sleep Scale Version 2, Montreal Cognitive Assessment, the Scale for Evaluation of Neuropsychiatric Disorders in Parkinson's Disease and the Clinical Impression of Severity Index for PD ( CISI ‐ PD ). For test?retest analysis, a second administration of the PDCS was carried out in 61 stable patients (as per the CISI ‐ PD ) in 7–14?days after the first evaluation. The PDCS is a novel scale for PD with a total of 17 items divided into four domains: motor, non‐motor, treatment complications and disability. Results Parkinson's Disease Composite Scale mean and median values were close. Skewness values were into the criterion limits (?1 to +1). The complete range of scores was covered for 14 of the 17 items (83.4%). A floor effect of 25.26% and 28.25% was observed in the complications and disability level dimensions due to the proportion of patients free of these difficulties. No relevant floor or ceiling effect was observed for the PDCS total score (1.03% and 0.52%, respectively). The stability of the scale appeared excellent with most items meeting weighted kappa and intraclass correlation coefficient values 0.80. The convergent validity of the PDCS with corresponding scores of the MDS ‐ UPDRS showed high correlation values ( r S ?≥?0.60). The internal validity was into acceptable limits, with the majority of values higher than the minimal 0.30 threshold. The standard error of measurement suggested a satisfactory precision (SEM?3.81, 30% of the PDCS total score standard deviation). Conclusion The PDCS appears to be a feasible, acceptable, reproducible and valid scale.
机译：背景和目的目的是验证帕金森病复合标尺（PDC）。方法该研究包括194个帕金森病（PD）五个国家的患者。调查人员完成了以下规模：PDCS，运动障碍社会统一帕金森病评级规模（MDS - updrs），帕金森病睡眠等级2，蒙特利尔认知评估，评估帕金森病中神经精神疾病的规模和严重程度的临床印象。 PD索引（CISI - PD）。对于测试？重新分析，在7-14次稳定的患者（根据CISI-PD）在第一次评估后的日子中进行第二次PDC施用PDC。 PDC是PD的新规模，总共17项分为四个域：电机，非运动，治疗并发症和残疾。结果帕金森氏病复合规模平均值和中位数近。偏斜值是标准限制（？1至+1）。 17项中的14项（83.4％）涵盖了完整的分数范围。由于没有这些困难的患者的比例，在并发症和残疾水平尺寸中，观察到25.26％和28.25％的地板效应。对于PDCS总得分（分别为1.03％和0.52％），没有观察到相关的楼层或天花板效果。大多数项目会满足加权κ和脑内相关系数值＆ 0.80的大多数项目出现了优异的稳定性。具有相应分数的MDS - UPDRS的PDC的收敛有效性显示出高的相关值（R S？≥≤0.60）。内部有效性是可接受的限制，大多数值高于最小的0.30阈值。测量标准误差表明了令人满意的精度（SEM？3.81，30％的PDCS总得分标准偏差）。结论PDC似乎是可行，可接受，可重复和有效的规模。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号